BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $390.00.

ONC has been the subject of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and set a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wolfe Research initiated coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective for the company. Finally, Barclays boosted their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $279.93 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The firm has a 50-day simple moving average of $302.13 and a 200 day simple moving average of $318.21. The company has a market cap of $30.71 billion, a PE ratio of 62.62 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion during the quarter. On average, sell-side analysts anticipate that BeOne Medicines will post 5.65 EPS for the current year.

Insider Activity

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.59, for a total transaction of $65,633.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Alessandro Riva sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.51, for a total transaction of $65,616.12. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 1,641 shares of company stock valued at $505,791. Company insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ONC. Cetera Investment Advisers acquired a new position in BeOne Medicines during the 2nd quarter valued at about $455,000. Rhumbline Advisers acquired a new position in BeOne Medicines during the 2nd quarter valued at about $275,000. Arrowstreet Capital Limited Partnership acquired a new position in BeOne Medicines during the 2nd quarter valued at about $505,000. Invesco Ltd. acquired a new position in BeOne Medicines during the 2nd quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC acquired a new position in BeOne Medicines during the 2nd quarter valued at about $68,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.